The UK BioIndustry Association (BIA) and Informa Pharma Intelligence have published figures revealing a strong start to 2019 for venture capital investment in UK biotech, despite the uncertainties of Brexit.
Gene and cell therapy firm Oxford Biomedica is to invest £4 million to build digital and robotics capabilities that will help manufacture the next generation of cutting edge therapies.
Merck KGaA signs potential $1 billion deal with UK biotech, which further consolidating F-star’s growing reputation within the industry, only recently being named Life Science Innovation champion at Business Weekly Awards.